TABLE 2.

Demographics characteristics of the study participants – initial testing (n = 34) and final testing (n = 26).

		Initial testing (n = 34)		Final testing (n = 26)
		Mean (± SD)	Range	Mean (± SD)	Range
Age (Years)		67.4 (± 14.9)	25–91	59.1 (± 18.2)	21–84
Time since Diagnosis		3.7 (± 5.6)	0.13–26	6.4 (± 7.2)	0.03–22
(years)
		n	%	n	%
Sex	Male	19	55.9	17	65.4
	Female	15	44.1	9	34.6
Ethnic Origin	White	33	97.1	25	96.2
	Black British	1	2.9	1	3.8
Disease Type	AML	9	26.5	1	3.8
	ALL	0	0.0	1	3.8
	CLL	2	5.9	0	0
	MM	13	38.2	4	15.4
	ANHL	3	8.8	5	19.2
	INHL	4	11.8	6	23.1
	CML	0	0.0	2	7.7
	MPN	1	2.9	1	3.8
	MDS	1	2.9	2	7.7
	HL	1	2.9	4	15.4
Disease State	Stable	7	11.7	4	15.4
	Remission	12	20.0	14	53.8
	Progressing	5	8.3	8	30.8
	Unknown	10	16.7	–	–

n, number of patients recruited; SD, standard deviation; AML, acute myeloid leukemia; ALL, acute lymphoid leukemia; CLL, chronic lymphoid leukemia; MM, multiple myeloma; ANHL, aggressive non-Hodgkin lymphoma; INHL, indolent non-Hodgkin lymphoma, CML. Chronic myeloid leukemia; MPN, myeloproliferative neoplasm; MDS, myelodysplastic syndromes; HL, Hodgkin lymphoma.